Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Hookipa Biotech
Biotech
Hookipa, having sold off vaccines to Gilead, opts to wind down
With its Poolbeg merger plans having bitten the dust and key assets sold to Gilead, Hookipa Pharma has decided it’s time to shut up shop completely.
James Waldron
Jul 21, 2025 3:15am
Gilead pays partner Hookipa $10M for HBV, HIV vaccines
May 22, 2025 10:10am
Hookipa walks back Poolbeg purchase plan
Feb 20, 2025 1:34pm
Poolbeg combines with Hookipa, while Vincerx braces for layoffs
Jan 2, 2025 5:59am
Hookipa, reeling from Roche's KRAS cull, lays off 30% of team
Jan 29, 2024 9:21am
BioMarin CEO replaces commercial chief—Chutes & Ladders
Jan 19, 2024 8:30am
